A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
← catalyst calendarNCT07069712 · readout in 441 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Parexel.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
100estimated
Sites
70
Countries
Canada, China, Georgia +8
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-07-17 | actual | When the study began enrolling |
| Primary completion | 2027-11-03 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-16 | estimated | The whole study's end, after follow-up |
| First posted | 2025-07-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Gastroesophageal Adenocarcinoma
Interventions
- Drug: Sonesitatug Vedotin — also filed as AZD0901
- Drug: Rilvegostomig — also filed as AZD2936
- Drug: Trastuzumab Deruxtecan (T-DXd) — also filed as DS-8201a
- Drug: Capecitabine
- Drug: 5-Fluorouracil (5-FU)
- Drug: FLOT Chemotherapy
- Drug: Calcium folinate — also filed as Leucovorin
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with adverse events (AEs) and serious adverse events (SAEs)
measured Until sub-study completion, up to 38 months
Percentage of participants with pathological complete response (pCR)
measured Until sub-study completion, up to 38 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed